Latest: FDA Approves New Biosimilar for Oncology Treatment

Alzheimer Psychosis Agent ACP-204 Shows No Impact on Corrected QT Intervals in Phase 1 Analysis

by Neurology Live

13 September, 2025

0 Mins

New findings reveal ACP-204 shows no significant QT interval prolongation in healthy adults, supporting its safety for Alzheimer disease psychosis treatment.

Tags:

Author

Neurology Live

Vinay Prasad, in surprise reversal, to rejoin FDA after abrupt departure

Cervical medial branch blocks may offer therapeutic benefit for facet-mediated neck pain

📢

300x250 Banner

Alzheimer Psychosis Agent ACP-204 Shows No Impact on Corrected QT Intervals in Phase 1 Analysis

Tags:

Neurology Live

Vinay Prasad, in surprise reversal, to rejoin FDA after abrupt departure

Cervical medial branch blocks may offer therapeutic benefit for facet-mediated neck pain

Recent Content

COPD Biologics: Early Treatment Insights

Antihypertensive Medication Guidelines

Juvenile Arthritis Care Transition